Xeris Biopharma Holdings, Inc. XERS Stock Issued During Period, Value, Conversion of Convertible Securities
Stock Issued During Period, Value, Conversion of Convertible Securities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s stock issued during period, value, conversion of convertible securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s stock issued during period, value, conversion of convertible securities?
- Xeris Biopharma Holdings, Inc. (XERS) reported stock issued during period, value, conversion of convertible securities of $0 in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s stock issued during period, value, conversion of convertible securities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s stock issued during period, value, conversion of convertible securities decreased by 100.0% year-over-year, from $3.19M to $0.
- What does stock issued during period, value, conversion of convertible securities mean?
- Measures the total value of common stock issued upon the conversion of convertible debt or other convertible securities into equity. This metric provides insight into the dilution of existing shareholders and the reduction of long-term debt obligations through the exercise of conversion features.